Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
48.85 USD | +1.60% | -10.63% | +1.92% |
May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
Evolution of the average Target Price on Korro Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Korro Bio, Inc.
HC Wainwright | |
RBC Capital Markets | |
BMO Capital | |
Piper Sandler | |
Baird | |
Chardan Research | |
Oppenheimer | |
Cormark Securities | |
Goldman Sachs | |
B. Riley | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- KRRO Stock
- Consensus Korro Bio, Inc.